A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

Inclusion Criteria: * Have a histological or cytological diagnosis of cancer (solid tumour), with clinical or radiologic evidence of locally advanced and/or metastatic disease, for which no life-prolonging therapy exists * Have the presence of measurable and/or nonmeasurable disease as defined by the Response Evaluation Criteria In Solid Tumours * Have Body Surface Area (BSA) greater than or equal to (≥)1.62 meter squared (m²) and less than or equal to (≤) 1.90 m² * Have adequate organ function * Have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale * Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 1 full cycle of treatment (beyond the initial \[¹⁴C\]prexasertib dose) Exclusion Criteria: * Have received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device * Have serious pre-existing medical conditions (left to the discretion of the investigator) * Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required) * Have current haematologic malignancies or acute or chronic leukaemia * Have an active fungal, bacterial, and/or known viral infection * Have participated in a ¹⁴C (carbon) study within the last 6 months prior to screening for this study * Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results